Leonard Zehr, Author at BioTuesdays

Feature

Peptilogics lead peptide platform targeting serious joint replacement infections

Peptilogics is working to change the treatment paradigm of periprosthetic joint infection (PJI), a serious condition that can result from joint replacement surgery. The company is preparing for a registrational clinical...

May 9, 2023

Executive Moves

PharmaJet names Nathalie Landry as CSO

PharmaJet appointed Nathalie Landry as chief scientific officer to provide strategic leadership and ensure the company’s clinical and scientific programs align with its global commercial expansion. PharmaJet’s pipeline...

May 2, 2023

Feature

SynaptixBio targeting rare disease, TUBB4A leukodystrophy, virtually

UK based biotechnology company SynaptixBio is developing the world’s first life-saving medicine for TUBB4A leukodystrophy, a rare genetic neurodegenerative disease that affects approximately 1,600 newborn babies and...

May 2, 2023

Developments

Morphic posts positive cohort data in ulcerative colitis

Morphic Therapeutic (NASDAQ:MORF) reported positive topline data from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057, an oral small molecule inhibitor of the α4β7 integrin, in adults with...

April 25, 2023

Feature

EyePoint focused on long-lasting treatments for wet AMD and DR

EyePoint Pharmaceuticals (NASDAQ:EYPT) is advancing its lead drug candidate, EYP-1901, in two Phase 2 clinical trials as a potential six-month treatment for wet age-related macular degeneration (AMD) and a potential...

April 25, 2023

Developments

Hepion to present data on synergistic effects of rencofilstat with anti-PD1 at AACR

Daren Ure, Ph.D., CSO of Hepion Pharmaceuticals (NASDAQ:HEPA) will present an abstract on April 18 highlighting the company’s lead drug candidate, rencofilstat, at the American Association for Cancer Research annual...

April 18, 2023

Feature

Alaunos attacking solid tumors with cutting-edge TCR-T cell therapies

Alaunos Therapeutics (NASDAQ:TCRT) is developing a library of T-cell receptor (TCR) cell therapies with the potential to revolutionize the treatment of solid tumors.

April 18, 2023

Feature

Rezolute focused on paradigm shift treating DME

Rezolute (NASDAQ:RZLT) is working on therapies targeting both ends of the spectrum of dysregulated glucose. It has now entered Phase 2 with an oral therapy to treat diabetic macular edema (DME), a big market...

April 11, 2023

Developments

iBio discovers new panel of CD3 T-cell binding antibodies using AI epitope steering platform

iBio (NYSEA:IBIO) announced the discovery of a panel of CD3 T-cell binding antibodies, representing an important first step for the company into bispecific immuno-oncology therapies. T-cell-redirecting bispecific...

April 5, 2023

Feature

KeifeRx developing oral TKIs for neurodegenerative and immune diseases

Closely-held KeifeRx is developing optimized, low dose, oral tyrosine kinase inhibitors (TKIs) for the treatment of multiple neurodegenerative and immune diseases.

April 4, 2023

Author - Leonard Zehr

Peptilogics lead peptide platform targeting serious joint replacement infections

PharmaJet names Nathalie Landry as CSO

SynaptixBio targeting rare disease, TUBB4A leukodystrophy, virtually

Morphic posts positive cohort data in ulcerative colitis

EyePoint focused on long-lasting treatments for wet AMD and DR

Hepion to present data on synergistic effects of rencofilstat with anti-PD1 at AACR

Alaunos attacking solid tumors with cutting-edge TCR-T cell therapies

Rezolute focused on paradigm shift treating DME

iBio discovers new panel of CD3 T-cell binding antibodies using AI epitope steering platform

KeifeRx developing oral TKIs for neurodegenerative and immune diseases

General

More